Neurocrine reports positive results of Ingrezza in chorea study

Neurocrine announced interim results from the ongoing open-label Kinect-HD2 study about Ingrezza capsules when used for the long-term treatment of adults with chorea associated with Huntington’s disease. Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. These data will be presented at the 30th Annual Meeting of the Huntington Study Group on November 2-4 in Phoenix. Both studies contributed to the recent FDA approval of Ingrezza for chorea associated with HD. Concomitant antipsychotic use is also being explored in the open-label study. More than half of participants – 60.9% – and investigators – 58.9% – rated symptoms as “much improved” or “very much improved” at Week 6, and about three-quarters of participants and investigators rated symptoms as “much improved” or “very much improved” by Week 50. The most common treatment-emergent adverse events at the time of the analysis were consistent with those observed in KINECT-HD, including falls, fatigue and somnolence. Neurocrine Biosciences will also present new data from a Phase 3 Trial of Valbenazine for the Treatment of Chorea Associated With Huntington’s Disease. Significant improvements in truncal chorea and gait asymmetry measures were seen from baseline to maintenance following the Week 10 visit in the INGREZZA-treated group compared to placebo. These findings support how digital measurements can be used to detect meaningful symptom changes in individuals with HD to improve clinical research and care.